Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
IARTPRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
IART(NASDAQ:IART) PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
IARTNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $25
IARTJP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $12
IARTWells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13
IARTIntegra Lifesciences Lowers FY2025 Adj EPS Guidance from $2.41-$2.51 to $2.19-$2.29 vs $2.46 Est; Affirms FY2025 Sales Guidance of $1.65B-$1.72B vs $1.68B Est
IARTIntegra Lifesciences Sees Q2 Adj EPS $0.40-$0.45 vs $0.57 Est; Sees Sales $390.000M-$400.000M vs $417.04M Est
IARTIntegra Lifesciences Q1 Adj. EPS $0.41 Misses $0.43 Estimate, Sales $382.65M Beat $381.17M Estimate
IARTTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $19
IARTArgus Research Upgrades Integra Lifesciences to Buy
IARTCitizens Capital Markets Reiterates Market Outperform on Integra Lifesciences, Maintains $35 Price Target
IARTIntegra LifeSciences Sees Q1 Revenue Of $375M - $385M Vs. $411.71M Est; Adj EPS Of $0.40 - $0.45 Vs. $0.56 Est.
IARTIntegra LifeSciences Sees FY15 Adj EPS Of $2.41 - $2.51 Vs. $2.51 Est.
IARTIntegra LifeSciences Sees FY25 Revenue Of $1.650B - $1.715B Vs. $1.71B Est.
IARTIntegra Lifesciences Q4 Adj $0.97 Beats $0.86 Estimate, Sales $442.64M Miss $445.15M Estimate
IARTCitigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $22
IARTWhy Is Integra LifeSciences Stock Soaring On Monday?
IARTIntegra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.
Integra LifeSciences Expects Q4 2024 Revenue of $441M-$451M Compared To Consensus $448.474M
IARTIntegra LifeSciences Expects Q4 2024 Adjusted EPS Of $0.81-$0.89 Compared To Consensus Of $0.87
IARTIntegra LifeSciences Expects 2024 Adjusted EPS Of $2.41-$2.49 Compared To Prior Guidance Of $2.41-$2.57 Vs $2.45 Est.
IARTIntegra LifeSciences Expects 2024 Revenue of $1.609B-$1.619B Compared To Prior Guidance Of $1.609B-$1.629B Vs $1.612B Est.
IARTIntegra Lifesciences Q3 2024 Adj EPS $0.41 Beats $0.39 Estimate, Sales $380.83M Beat $375.78M Estimate
IARTIntegra LifeSciences Has Appointed Mojdeh Poul As The New President And Chief Executive Officer, Effective January 6, 2025, Succeeding Jan De Witte, Who Will Remain President And CEO Until January 6, 2025
IARTCitigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $28
IARTLooking Into Integra Lifesciences's Return On Capital Employed
IARTAccording to Benzinga Pro, during Q1, Integra Lifesciences (NASDAQ:IART) earned $32.90 million, a 27.51% increase from the preceding quarter. Integra Lifesciences's sales decreased to $376.64 million, a 7.12% change since Q4.
